The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 01, 2023

Filed:

Apr. 08, 2021
Applicant:

University of Zurich, Zurich, CH;

Inventors:

Uwe Zangemeister-Wittke, Embrach, CH;

Claudio Di Paolo, Zurich, CH;

Dominique Christine Tschudi, Zurich, CH;

Nicholas Ronald Glover, Oakville, CA;

Dimitri Peter Fitsialos, Toronto, CA;

Assignee:

University of Zürich, Zürich, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 14/21 (2006.01); C07K 14/34 (2006.01); A61K 47/68 (2017.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 45/06 (2013.01); A61K 47/6829 (2017.08); A61K 47/6861 (2017.08); A61K 47/6865 (2017.08); C07K 14/21 (2013.01); C07K 14/34 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form ofexotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.


Find Patent Forward Citations

Loading…